Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.57 |
| ▸ | AXL | P30530 | 1/20 | 0.48 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.48 |
| ▸ | HAT1 | O14929 | 3/20 | 0.46 |
| ▸ | EP300 | Q09472 | 3/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 5/20 | 0.46 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.45 |
| ▸ | TUBB | P07437 | 1/20 | 0.45 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.45 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.45 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.45 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.45 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.45 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.45 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.45 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.45 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.45 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.45 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26701081 | 0.87 | AXL (0.63) | ROCK2ROCK1AXLIMPDH2HAT1 | |
| SCHEMBL6325476 | 0.86 | NR4A2 (0.47) | ROCK2ROCK1HAT1EP300NR4A2 | |
| SCHEMBL6332971 | 0.85 | NR4A2 (0.65) | ROCK2ROCK1HAT1EP300NR4A2 | |
| SCHEMBL26704632 | 0.83 | IMPDH2 (0.51) | ROCK2ROCK1IMPDH2HAT1EP300 | |
| SCHEMBL1763120 | 0.80 | CYP2D6 (0.45) | AXLNR4A2GSK3BHASPIN | |
| SCHEMBL6029944 | 0.78 | NR4A2 (0.73) | NR4A2TUBB1 | |
| SCHEMBL29688274 | 0.77 | NR4A2 (0.47) | ROCK1AXLNR4A2HASPIN | |
| SCHEMBL6334125 | 0.77 | NR4A2 (0.74) | NR4A2 | |
| SCHEMBL3236458 | 0.77 | NR4A2 (0.47) | ROCK1AXLNR4A2HASPIN | |
| SCHEMBL6029933 | 0.77 | NR4A2 (0.57) | NR4A2TUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867198-B2 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
| EP-1242420-A2 | AGENTS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001044247-A2 | AGENTS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | MKI67, CDKN1A, CDK1 | ROCK2 393/4885ROCK1 220/4885AXL 3534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.